References
- Barrios V , CalderónA, EscobarC, de la FigueraM . Patients with atrial fibrillation in a primary care setting: Val-FAAP study . Rev. Esp. Cardiol.65 ( 1 ), 47 – 53 ( 2012 ).
- Kirchhof P , BenussiS, KotechaDet al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS . Eur. Heart J.37 ( 38 ), 2893 – 2962 ( 2016 ).
- Hart RG , PearceLA, AguilarMI . Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation . Ann. Intern. Med.146 ( 12 ), 857 – 867 ( 2007 ).
- Barrios V , EscobarC, CalderónAet al. Use of antithrombotic therapy according to CHA2DS2-VASc score in patients with atrial fibrillation in primary care . Rev. Esp. Cardiol.67 ( 2 ), 150 – 151 ( 2014 ).
- Ruff CT , GiuglianoRP, BraunwaldEet al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials . Lancet383 ( 9921 ), 955 – 962 ( 2014 ).
- O’Brien EC , KimS, ThomasLet al. Clinical characteristics, oral anticoagulation patterns, and outcomes of medicaid patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) registry . J. Am. Heart Assoc.5 ( 5 ) ( 2016 ).
- Yu AYX , MaloS, SvensonLW, WiltonSB, HillMD . Temporal trends in the use and comparative effectiveness of direct oral anticoagulant agents versus warfarin for nonvalvular atrial fibrillation: a Canadian population-based study . J. Am. Heart Assoc.6 ( 11 ), pii:e002721 ( 2017 ) ( Epub ahead of print ).
- Patel MR , MahaffeyKW, GargJet al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation . N. Engl. J. Med.365 ( 10 ), 883 – 891 ( 2011 ).
- Tanislav C , MildeS, SchwartzkopffS, MisselwitzB, SiewekeN, KapsM . Baseline characteristics in stroke patients with atrial fibrillation: clinical trials versus clinical practice . BMC Res. Notes8, 262 ( 2015 ).
- Barrios V , EscobarC . From clinical trials to clinical practice. Experience with rivaroxaban in the anticoagulant treatment of patients with nonvalvular atrial fibrillation . Semergen43 ( 3 ), 222 – 229 ( 2017 ).
- Coleman CI , AntzM, BowrinKet al. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study . Curr. Med. Res. Opin.32 ( 12 ), 2047 – 2053 ( 2016 ).
- Camm AJ , AmarencoP, HaasSet al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation . Eur. Heart J.37 ( 14 ), 1145 – 1153 ( 2016 ).
- Tamayo S , Frank PeacockW, PatelMet al. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27467 patients taking rivaroxaban . Clin. Cardiol.38 ( 2 ), 63 – 68 ( 2015 ).
- Beyer-Westendorf J , FörsterK, PannachSet al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry . Blood124 ( 6 ), 955 – 962 ( 2014 ).